Get started
Author

Claire L. McWhirter

Observed names: C. McWhirter, Claire L McWhirter, Claire McWhirter
ORCID: 0000-0003-3316-205X
Observed ORCID: 0000-0003-3316-205X
OpenAlex ID: A5003379838
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
2016 · Vanessa S. Rodrik-Outmezguine, Masanori Okaniwa, et al. · Nature · 493
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
2021 · Diana Zatreanu, Helen M. R. Robinson, et al. · Nature Communications · 398
PDF
Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site
2016 · Jack C Exell, Mark J Thompson, et al. · Nature Chemical Biology · 82
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma
2017 · James S. Scott, Sébastien L. Degorce, et al. · Journal of Medicinal Chemistry · 59
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta
2022 · Martin L. Stockley, Amanda Ferdinand, et al. · Journal of Medicinal Chemistry · 53
Mechanistic Study of Protein Phosphatase-1 (PP1), A Catalytically Promiscuous Enzyme
2008 · Claire McWhirter, Elizabeth A. Lund, et al. · Journal of the American Chemical Society · 46
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
2021 · M. Raymond V. Finlay, Peter Barton, et al. · Journal of Medicinal Chemistry · 39
Development of a High-Throughput Fluorescence Polarization DNA Cleavage Assay for the Identification of FEN1 Inhibitors
2013 · Claire McWhirter, Michael Tonge, et al. · SLAS DISCOVERY · 26
Kinetic mechanisms of covalent inhibition
2021 · Claire McWhirter · Annual reports in medicinal chemistry · 18
Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity
2014 · William McCoull, Edward J. Hennessy, et al. · MedChemComm · 18
High-throughput kinetics in drug discovery
2024 · Maria Filipa Pinto, Julija Sirina, et al. · SLAS DISCOVERY · 15
PDF
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy
2025 · Eeson Rajendra, Claudio A Lademann, et al. · Nucleic Acids Research · 7
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor
2025 · Sam E. Mann, Julien Lefranc, et al. · Journal of Medicinal Chemistry · 7
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1
2025 · Sam E. Mann, Owen A. Davis, et al. · Journal of Medicinal Chemistry · 4
Abstract P056: Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
2021 · Diana A. Zatreanu, Helen M. R. Robinson, et al. · Molecular Cancer Therapeutics · 4
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al. · Clinical Cancer Research · 2
139 (PB127): ART6043: a first-in-class clinical DNA Polymerase Theta polymerase domain inhibitor for potentiating PARP inhibitor efficacy
2024 · H. Robinson, V. Grinkevich, et al. · European Journal of Cancer · 1
Correction to “Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta”
2023 · Martin L. Stockley, Giovanni Benedetti, et al. · Journal of Medicinal Chemistry · 1
PDF
Abstract 5697: Targeting PARP inhibitor resistance with Polθ inhibitors
2022 · Diana Zatreanu, Helen Robinson, et al. · Cancer Research · 1
Abstract 2147: Overcoming mTOR resistance mutations with a new generation mTOR inhibitor
2016 · Vanessa S. Rodrik-Outmezguine, Masanori Okaniwa, et al. · Cancer Research · 1
Data from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Supplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
2026 · Helen M.R. Robinson, Vera Grinkevich, et al.
Abstract 246: Discovery and mechanistic characterisation of the first oral bioavailable FEN1 inhibitor for treatment of HRD and EWS cancers and combination with various DDR inhibitors.
2026 · Lars T. Burgdorf, Julien Lefranc, et al. · Cancer Research
High-throughput evaluation of enzyme inhibitor mode-of-action
2026 · Amaury E. Fernández-Montalván, Victoria Georgi, et al. · Methods in enzymology on CD-ROM/Methods in enzymology
Human Fen1 in complex with an N-hydroxyurea compound
2016 · J.C. Exell, M.J. Thompson, et al. · Worldwide Protein Data Bank
Works count: 26
Citation count: 1,275
H-index: 11
I10-index: 11
Year
Topic
Type